What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis

[1]  D. Della-Morte,et al.  Genetic susceptibility to cerebrovascular disease , 2016, Current opinion in lipidology.

[2]  J. Denny,et al.  The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy , 2016, The Pharmacogenomics Journal.

[3]  Yun-Bo Zhang,et al.  E670G polymorphism of PCSK9 gene of patients with coronary heart disease among Han population in Hainan and three provinces in the northeast of China. , 2016, Asian Pacific journal of tropical medicine.

[4]  L. Griffiths,et al.  The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis , 2015, Scientific Reports.

[5]  Chun-yan Ma,et al.  The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis , 2015, Lipids in Health and Disease.

[6]  Fen Liu,et al.  Relationships between genetic polymorphisms of E670G in PCSK9 gene and coronary artery disease: a meta-analysis. , 2015, International journal of clinical and experimental medicine.

[7]  B. Balkau,et al.  The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis , 2015, Diabetologia.

[8]  S. Porntadavity,et al.  Combined PCSK9 and APOE Polymorphisms are Genetic Risk Factors Associated with Elevated Plasma Lipid Levels in a Thai Population , 2015, Lipids.

[9]  Jian‐Jun Li,et al.  PCSK9: A key factor modulating atherosclerosis. , 2015, Journal of atherosclerosis and thrombosis.

[10]  K. Pooley,et al.  Genetic variation and gastric cancer risk: a field synopsis and meta-analysis , 2015, Gut.

[11]  U. Laufs,et al.  Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9) , 2015, Basic Research in Cardiology.

[12]  R. Dufour,et al.  PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia: A Cross-Sectional Cohort Study , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[13]  Matti Pirinen,et al.  Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins , 2014, Nature Communications.

[14]  T. Tuerxun,et al.  Correlation of PCSK9 Gene Polymorphism with Cerebral Ischemic Stroke in Xinjiang Han and Uygur Populations , 2014, Medical science monitor : international medical journal of experimental and clinical research.

[15]  Thomas A. Lagace.  PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells , 2014, Current opinion in lipidology.

[16]  M. Hirata,et al.  Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. , 2014, Journal of clinical lipidology.

[17]  N. Wu,et al.  PCSK9 gene mutations and low-density lipoprotein cholesterol. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[18]  W. Jomaa,et al.  Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort , 2014, Journal of Molecular Neuroscience.

[19]  U. Laufs,et al.  Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. , 2013, Journal of the American College of Cardiology.

[20]  S. Duan,et al.  Association between PCSK9 and LDLR gene polymorphisms with coronary heart disease: case-control study and meta-analysis. , 2013, Clinical biochemistry.

[21]  L. Bernier,et al.  Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations , 2013, Lipids in Health and Disease.

[22]  Rui-Xing Yin,et al.  Proprotein Convertase Subtilisin/Kexin Type 9 Gene E670G Polymorphism Interacts with Alcohol Consumption to Modulate Serum Lipid Levels , 2012, International journal of medical sciences.

[23]  W. März,et al.  Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency , 2013, The Journal of clinical endocrinology and metabolism.

[24]  S. Kathiresan,et al.  Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population , 2010, Journal of Lipid Research.

[25]  Børge G Nordestgaard,et al.  PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. , 2010, Journal of the American College of Cardiology.

[26]  K. Berge,et al.  Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[27]  S. Humphries,et al.  Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9. , 2009, Clinical chemistry.

[28]  M. Fornage,et al.  Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels: The Coronary Artery Risk Development in Young Adults Study , 2009, Circulation. Cardiovascular genetics.

[29]  Julian Little,et al.  Systematic Reviews of Genetic Association Studies , 2009, PLoS medicine.

[30]  L. Hsu,et al.  The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan , 2009, Clinical chemistry and laboratory medicine.

[31]  J. Ordovás,et al.  Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. , 2008, Atherosclerosis.

[32]  I. Kullo,et al.  Molecular population genetics of PCSK9: a signature of recent positive selection , 2008, Pharmacogenetics and genomics.

[33]  Siobhan M. Dolan,et al.  Assessment of cumulative evidence on genetic associations: interim guidelines. , 2008, International journal of epidemiology.

[34]  S. Humphries,et al.  The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. , 2007, Clinical science.

[35]  M. Pandolfo,et al.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke , 2007, PloS one.

[36]  J. Ioannidis,et al.  Reporting of Systematic Reviews: The Challenge of Genetic Association Studies , 2007, PLoS medicine.

[37]  A. Prat,et al.  The proprotein convertases are potential targets in the treatment of dyslipidemia , 2007, Journal of Molecular Medicine.

[38]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[39]  F. Beil,et al.  The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women , 2006, BMC Medical Genetics.

[40]  A. Gotto,et al.  A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. , 2005, Journal of the American College of Cardiology.

[41]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[42]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[43]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[44]  T. Leren,et al.  PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum. , 2014, The Biochemical journal.

[45]  Liu Zhong-min.  A study on the correlation between E670G polymorphism of PCSK9 gene and coronary artery disease in the Guangdong population , 2011 .

[46]  D. Noto,et al.  Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. , 2010, Atherosclerosis.

[47]  Nathaniel Rothman,et al.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. , 2004, Journal of the National Cancer Institute.